Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Rhea-AI Summary
Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotech focused on blood coagulation disorders, will participate in the 2026 Jefferies Global Healthcare Conference in New York.
A fireside chat is scheduled for Thursday, June 4, 2026 at 9:20 AM ET, with a live webcast and replay available on Hemab’s investor website.
Positive
- None.
Negative
- None.
News Market Reaction – COAG
In the May 27 session, COAG gained 2.73%, reflecting a moderate positive market reaction. Argus tracked a peak move of +3.4% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 21 | Q1 2026 earnings | Positive | -0.6% | Reported Q1 results with cash runway and outlined clinical and financing milestones. |
| May 04 | Upsized IPO close | Positive | -1.3% | Closed upsized IPO at $18 per share with $346.7M gross proceeds and Nasdaq listing. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive financing and milestone updates were followed by modest negative price reactions, indicating a tendency for the stock to trade lower after seemingly constructive news.
Over May 2026, Hemab transitioned into a public company and reported its first results as a Nasdaq issuer. On May 4, it closed an upsized IPO, selling 19,262,500 shares at $18.00 for gross proceeds of $346.7 million. On May 21, it reported Q1 2026 results, highlighting cash and securities of $163.5 million and clinical and financing milestones. Both events saw small negative 24-hour price reactions despite constructive developments.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 27, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced that members of the Hemab Therapeutics management team will present and host investor meetings at the 2026 Jefferies Global Healthcare Conference.
2026 Jefferies Global Healthcare Conference
Fireside Chat: Thursday, June 4, 2026 at 9:20 AM ET
Location: New York, NY
A live webcast of the fireside chat will be available for replay under “Events & Presentations” section in the Investors section of Hemab Therapeutics’ website at hemab.com.
About Hemab Therapeutics
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab’s mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, and HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease.
Learn more at hemab.com. Follow us on LinkedIn, Facebook, Instagram, and X.
Media:
Deerfield
Peg Rusconi
peg.rusconi@deerfieldgroup.com
Investors:
Hemab Therapeutics
Mads Behrndt
investors@hemab.com
